Literature DB >> 28299178

DWCox: A density-weighted Cox model for outlier-robust prediction of prostate cancer survival.

Jinfeng Xiao1, Sheng Wang1, Jingbo Shang1, Henry Lin1, Doris Xin1, Xiang Ren1, Jiawei Han1, Jian Peng1.   

Abstract

Reliable predictions on the risk and survival time of prostate cancer patients based on their clinical records can help guide their treatment and provide hints about the disease mechanism. The Cox regression is currently a commonly accepted approach for such tasks in clinical applications. More complex methods, like ensemble approaches, have the potential of reaching better prediction accuracy at the cost of increased training difficulty and worse result interpretability. Better performance on a specific data set may also be obtained by extensive manual exploration in the data space, but such developed models are subject to overfitting and usually not directly applicable to a different data set. We propose DWCox, a density-weighted Cox model that has improved robustness against outliers and thus can provide more accurate predictions of prostate cancer survival. DWCox assigns weights to the training data according to their local kernel density in the feature space, and incorporates those weights into the partial likelihood function. A linear regression is then used to predict the actual survival times from the predicted risks. In the 2015 Prostate Cancer DREAM Challenge, DWCox obtained the best average ranking in prediction accuracy on the risk and survival time. The success of DWCox is remarkable given that it is one of the smallest and most interpretable models submitted to the challenge. In simulations, DWCox performed consistently better than a standard Cox model when the training data contained many sparsely distributed outliers. Although developed for prostate cancer patients, DWCox can be easily re-trained and applied to other survival analysis problems. DWCox is implemented in R and can be downloaded from https://github.com/JinfengXiao/DWCox.

Entities:  

Keywords:  Cox model; DREAM; Prostate cancer

Year:  2016        PMID: 28299178      PMCID: PMC5321125          DOI: 10.12688/f1000research.9434.1

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  14 in total

1.  Is the pleural fluid transudate or exudate? A revisit of the diagnostic criteria.

Authors:  J Joseph; P Badrinath; G S Basran; S A Sahn
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

2.  Generating survival times to simulate Cox proportional hazards models.

Authors:  Ralf Bender; Thomas Augustin; Maria Blettner
Journal:  Stat Med       Date:  2005-06-15       Impact factor: 2.373

3.  Using the outcome for imputation of missing predictor values was preferred.

Authors:  Karel G M Moons; Rogier A R T Donders; Theo Stijnen; Frank E Harrell
Journal:  J Clin Epidemiol       Date:  2006-06-19       Impact factor: 6.437

4.  Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Daniel P Petrylak; Nicholas J Vogelzang; Nikolay Budnik; Pawel Jan Wiechno; Cora N Sternberg; Kevin Doner; Joaquim Bellmunt; John M Burke; Maria Ochoa de Olza; Ananya Choudhury; Juergen E Gschwend; Evgeny Kopyltsov; Aude Flechon; Nicolas Van As; Nadine Houede; Debora Barton; Abderrahim Fandi; Ulf Jungnelius; Shaoyi Li; Ronald de Wit; Karim Fizazi
Journal:  Lancet Oncol       Date:  2015-03-03       Impact factor: 41.316

5.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

6.  Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent.

Authors:  Noah Simon; Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2011-03       Impact factor: 6.440

7.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.

Authors:  Oren Smaletz; Howard I Scher; Eric J Small; David A Verbel; Alex McMillan; Kevin Regan; W Kevin Kelly; Michael W Kattan
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

8.  Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

Authors:  Karim Fizazi; Karim S Fizazi; Celestia S Higano; Joel B Nelson; Martin Gleave; Kurt Miller; Thomas Morris; Faith E Nathan; Stuart McIntosh; Kristine Pemberton; Judd W Moul
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

9.  Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer.

Authors:  Motoki Shiga
Journal:  F1000Res       Date:  2016-11-16

10.  Imputing missing covariate values for the Cox model.

Authors:  Ian R White; Patrick Royston
Journal:  Stat Med       Date:  2009-07-10       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.